Based on the recent earnings call for Nektar, it is clear that the company has achieved significant progress and success in advancing its pipeline programs, particularly in the areas of immuno-oncology, immunology, and chronic pain. Nektar has formed strategic collaborations with industry leaders such as Bristol-Myers Squibb, AstraZeneca, and Daiichi Sankyo, indicating strong partnerships and potential for future growth.

The company's lead immuno-oncology program, NKTR-214, has shown promising results in combination with Bristol-Myers Squibb's anti-PD-1 agent Opdivo, and has the potential to fill a critical gap in the immune-oncology therapeutic regimens. Additionally, Nektar's diverse pipeline includes innovative approaches for the treatment of autoimmune diseases and chronic pain, with potential for significant impact on patient care.

Nektar has also achieved notable commercial success with its partnered products, such as MOVANTIK, which has shown robust growth in annual prescriptions and peak weekly prescriptions. The company's partnership with Shire for ADYNOVATE and its potential conditional approval for ONZEALD in Europe also reflect positive developments in its partnered portfolio.

Overall, Nektar's recent achievements and upcoming milestones position the company for excellent growth in 2017. Therefore, we recommend an 'overweight' investment stance on Nektar based on its strong pipeline, strategic collaborations, and commercial success in the market. The company's focus on addressing critical medical needs and advancing novel therapies makes it an attractive investment opportunity for long-term growth and success.